Table 2 Expression of Mcl-1 in oral cancers and precancerous lesions
From: Myeloid cell leukemia-1 expression in cancers of the oral cavity: a scoping review
Refs. | Subject sample type | Lesion type | Findings |
|---|---|---|---|
[92] | Human HNSCC | Human HNSCC | MCL-1 positively correlated with Bak expression |
[93] | Human HNSCC | HNSCC | Higher Mcl-1 associated with complete remission |
[26] | Human OSCC, OPML | OPML, OSCC | Upregulated in OPML, OSCC; associated with well-differentiated OSCC |
[32] | Human OSCC | OSCC | Upregulated in OSCC, associated with well-differentiated OSCC |
[94] | Human OSCC | OSCC | MCL-1 associated with reduced disease-free survival |
[95] | Human SGT | SGT | Upregulated in parotid tumors |
[96] | Human HNSCC | Oropharyngeal cancer | SNP in MCL-1 in association with HPV16 associated with oropharyngeal cancer |
[33] | Human OSCC | OSCC | MCL-1 upregulated in OSCC |
[29] | Human OPML | OPML | Better therapeutic response with higher Bak/Mcl-1 ratio |
[95] | Human serum with HNSCC | HNSCC | MCL-1 mRNA levels significantly upregulated in the serum of patients with HNSCC |
[30] | Human OSCC | OSCC | MCL-1Â L Upregulated in OSCC, associated with nodal metastasis, advanced tumor, reduced overall survivin |
[35] | Human SGT | SGT | Amplified in one case, grade 3 AdCC |
[27] | Human OPML | OPML | Upregulated in OPML |
[25] | Human OPML, OSCC | OPML, OSCC | Amplified in OPML and OSCC |
[38] | Human OSCC | OSCC | Increased expression of Mcl-1 in chemoresistant OSCC |
[31] | Human OSCC | OSCC | Overexpression of Mcl-1 in OSCC when compared with adjacent normal tissues |
[28] | Human OPML, OSCC | OPML, OSCC | Overexpression in OPML, OSCC. Associated with advanced tumors, recurrent tumors, and reduced overall survival |